SCHEMBL3117979

SCHEMBL3117979

CCOC(=O)c1nc(-c2cccs2)oc1-c1ccc(OC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 6/20 0.58
PDCD4 Q53EL6 1/20 0.58
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPT P10636 6/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
PKM P14618 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ADCY1 Q08828 1/20 0.45
GAA P10253 2/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 1/20 0.45
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
ESR1 P03372 1/20 0.44
CASP1 P29466 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3122330 0.85 KDM4E (0.51) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL3127984 0.84 IKBKB (0.54) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL16005699 0.83 TARBP2 (0.72) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL29158677 0.83 TARBP2 (0.72) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL11622240 0.81 TARBP2 (0.61) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL29158788 0.80 TARBP2 (0.66) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL13056699 0.79 TARBP2 (0.64) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL29158625 0.78 TARBP2 (0.67) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL13115485 0.77 TARBP2 (0.48) TARBP2PDCD4ALDH1A1KDM4EMAPT
SCHEMBL3119507 0.77 TARBP2 (0.62) TARBP2PDCD4ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 EP disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2014-09-18 US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 WO disclosed
EP-2170849-A1 OXAZOLE TYROSINE KINASE INHIBITORS Sareum Limited (GB) 2010-04-07 EP disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 TARBP2 4567/4885PDCD4 1434/4885ALDH1A1 1403/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 TARBP2 4567/4885PDCD4 1434/4885ALDH1A1 1403/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 TARBP2 4567/4885PDCD4 1434/4885ALDH1A1 1403/4885
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 TARBP2 4584/4885PDCD4 1306/4885ALDH1A1 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.